Cargando…
An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a seri...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519776/ https://www.ncbi.nlm.nih.gov/pubmed/34675646 http://dx.doi.org/10.2147/JPR.S314206 |
_version_ | 1784584522582458368 |
---|---|
author | Mattia, Consalvo Luongo, Livio Innamorato, Massimo Melis, Luca Sofia, Michele Zappi, Lucia Puntillo, Filomena |
author_facet | Mattia, Consalvo Luongo, Livio Innamorato, Massimo Melis, Luca Sofia, Michele Zappi, Lucia Puntillo, Filomena |
author_sort | Mattia, Consalvo |
collection | PubMed |
description | PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement ≥4 (Agree or Strongly agree). RESULTS: The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)”. A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion. CONCLUSION: Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients. |
format | Online Article Text |
id | pubmed-8519776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-85197762021-10-20 An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. Mattia, Consalvo Luongo, Livio Innamorato, Massimo Melis, Luca Sofia, Michele Zappi, Lucia Puntillo, Filomena J Pain Res Original Research PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement ≥4 (Agree or Strongly agree). RESULTS: The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)”. A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion. CONCLUSION: Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients. Dove 2021-10-11 /pmc/articles/PMC8519776/ /pubmed/34675646 http://dx.doi.org/10.2147/JPR.S314206 Text en © 2021 Mattia et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Mattia, Consalvo Luongo, Livio Innamorato, Massimo Melis, Luca Sofia, Michele Zappi, Lucia Puntillo, Filomena An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title | An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title_full | An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title_fullStr | An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title_full_unstemmed | An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title_short | An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. |
title_sort | italian expert consensus on the use of opioids for the management of chronic non-oncological pain in clinical practice: focus on buprenorphine. |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519776/ https://www.ncbi.nlm.nih.gov/pubmed/34675646 http://dx.doi.org/10.2147/JPR.S314206 |
work_keys_str_mv | AT mattiaconsalvo anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT luongolivio anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT innamoratomassimo anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT melisluca anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT sofiamichele anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT zappilucia anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT puntillofilomena anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT mattiaconsalvo italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT luongolivio italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT innamoratomassimo italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT melisluca italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT sofiamichele italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT zappilucia italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine AT puntillofilomena italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine |